Clinical experience suggests that Levetiracetam is a well-tolerated medication with minimal cognitive or sedative effects. Levetiracetam is a structural analogue of piracetam, a drug used as a nootropic (cognitive enhancing) agent in Europe. However, a recent placebo-controlled study of adjunctive levetiracetam therapy for intractable complex partial seizures showed several CNS adverse events more common than placebo, including somnolence, asthenia, and dizziness (Morrell et al., 2003). The occurrence of these specific cognitive adverse events were relatively modest ranging from one to seven per cent relative to placebo. Data detailing the cognitive and mood profile of levetiracetam in healthy older adults are limited. Kraemer and Edrich (2003) using pooled clinical trial data found no differences in the incidence of central nervous system events between elderly patients and younger adults in a large clinical trial. Similarly , the KEEPER trial found no difference in frequency of side effects to levetiracetam in younger verses adults over 65 (range 65 to>85) . The KEEPER trial was a phase IV study that has limited interpretability as it was open label (Ferrendelli et al., 2003). Clinical experience has been consistent in showing good tolerability in the elderly (French 2001 ;Cramer et al 2003a; Ferrendelli et al, 2003 ; Pryor and Ramsay, 2003 ; Ramsay et al,2003 ; Werz et al 2003 ; Alsaadi et al 2004). However, the neurocognitive and mood effects of levetiracetam in older adults have not yet been documented in well designed trials to specifically address this issue.